Gilead Sciences, Inc. $GILD Position Increased by Fluent Financial LLC

Fluent Financial LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 55.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,148 shares of the biopharmaceutical company’s stock after buying an additional 14,326 shares during the quarter. Gilead Sciences accounts for 1.8% of Fluent Financial LLC’s portfolio, making the stock its 14th largest position. Fluent Financial LLC’s holdings in Gilead Sciences were worth $4,451,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences in the 1st quarter valued at about $25,000. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences in the 1st quarter valued at about $29,000. Colonial Trust Advisors increased its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital increased its holdings in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.3%

GILD opened at $118.25 on Thursday. Gilead Sciences, Inc. has a 1-year low of $84.17 and a 1-year high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $146.73 billion, a price-to-earnings ratio of 23.56, a P/E/G ratio of 0.79 and a beta of 0.34. The business has a 50 day moving average of $114.48 and a 200-day moving average of $110.12.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GILD. Rothschild & Co Redburn upped their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday. Finally, Citigroup increased their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $117.67.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,402,130 in the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.